Hunan Province Tumor Hospital
81
35
35
20
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 81 trials
100.0%
+13.5% vs industry average
11%
9 trials in Phase 3/4
0%
0 of 20 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (81)
The Recurrence Gene Profiles of Adjuvant Osimertinib Therapy in Resected Non-Small-Cell Lung Cancer
Role: lead
Megestrol Acetate for First-Line Treatment of Malnourished Non-Small Cell Lung Cancer
Role: lead
Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progression
Role: lead
Postoperative Radiotherapy for Early-stage Oral Tongue Squamous Cell Carcinoma Patients With Risk Factors: a Prospective, Multicenter, Randomized Controlled, Open-labelled Trial
Role: collaborator
Effect of Infusion Timing on Pathologic Response to Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer
Role: lead
ctDNA Analysis to Monitor the Risk of Progression After First-line Immunotherapy in Patients With Advanced NSCLC
Role: collaborator
The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined with Lenvatinib in NSCLC.
Role: lead
Chemotherapy Combined with ICIs in First-line Alectinib Failed Patients with ALK-rearranged NSCLC
Role: lead
Clinical Study of Nanocrystalline Megestrol in Malnourished Patients With First-Line Non-Small Cell Lung Cancer
Role: lead
Effect of Time-of-Day (ToD) for Immunochemotherapy on PFS in NSCLC
Role: lead
Survival Outcomes of Lung Cancer
Role: lead
Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC
Role: lead
Efficacy and Safety of SKB264 in Combination With Pembrolizumab in Patients With Initially Unresectable Stage III NSCLC
Role: lead
Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation
Role: lead
Third-generation EGFR-TKI Plus Anlotinib as Maintenance for NSCLC With Small Cell Transformation After EGFR-TKI Resistance
Role: lead
AK112 Plus Platinum-based Chemotherapy for EGFR/ALK/ROS1 Positve NSCLC
Role: lead
A Study With Central Nervous System Metastatic EGFR Mutation Positive Non-small Cell Lung Cancer
Role: lead
ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma
Role: lead
Intrathecal Pemetrexed Combined With High-dose Furmonertinib and Beva for EGFR-m NSCLC With Leptomeningeal Metastases
Role: lead
Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR Mutant Advanced NSCLC-RW
Role: lead